UCB reports mixed epilepsy data

Adjunctive therapy with brivaracetam from UCB Group (Euronext:UCB) met the primary endpoint in one Phase III trial in epilepsy patients but missed in a second Phase III study. Each placebo-controlled trial enrolled 400 patients and had a primary endpoint of reductions in seizure frequency. UCB said the compound's efficacy appeared to differ between different patient subpopulations. ...